Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B019 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT06927466Phase 1Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22 CAR-T in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06927466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927466.